Business Wire

QNB Group: Financial Results for the Six Months Ended 30 June 2017

11.7.2017 16:14 | Business Wire

Jaa

QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the six months ended 30 June 2017, which is the highest in the history of QNB Group.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170711005906/en/

QNB Head office (Photo: Business Wire)

QNB Head office (Photo: Business Wire)

For the first six months of 2017, Net Profit reached QAR6.7 billion (USD1.8 billion), up by 7% compared to last year, demonstrating QNB Group’s success in resilience and maintaining strong growth while controlling costs.

Total assets reached QAR768 billion (USD211 billion), up by 11% from June 2016, the highest ever achieved by the Group. This was driven by a growth rate of 11% in loans and advances to reach QAR552 billion (USD152 billion). QNB Group was successful in attracting new customer deposits. These deposit mobilisation efforts resulted in increased customer funding by 15% to reach QAR562 billion (USD154 billion) from June 2016. This led to the Group’s loan to deposit ratio reaching 98.3%, compared with 101.7% in June 2016. This clearly demonstrates the success of QNB’s strategy to diversify its funding sources.

The Group’s prudent cost control policy and strong revenue generating capability helped to improve the efficiency ratio (cost to income ratio) to 29.3% as at 30 June 2017, from 30.4% in June 2016, which is considered one of the best ratios among financial institutions in the region.

The Group was able to maintain the ratio of non-performing loans to gross loans at 1.8%, a level considered one of the lowest amongst financial institutional in the MEA region, reflecting the high quality of the Group’s loan book and the effective management of credit risk. The Group’s conservative policy in regard to provisioning continued with the coverage ratio reaching 110% in 30 June 2017.

QNB Group benefits from a highly diversified international and local funding base spread across MEA, Europe and Asia. QNB has successfully diversified its wholesale funding pools in terms of currencies, tenors and product mix and follows a very conservative approach to manage its liquidity needs.

Based on this, the Group decreased its Loans to Deposit ratio to 98.3%, from 101.7% in June 2016 and improved liquid assets which comprise of cash and cash equivalents to QAR65 billion (USD18 billion) or 8% of total assets.

Total Equity increased by 1% from June 2016 to reach QAR 74 billion (USD20 billion) as at 30 June 2017. Earnings per Share reached QAR 7.0 (USD 1.91), compared to QAR 6.7(USD 1.85) in June 2016.

Capital Adequacy Ratio (CAR) calculated as per the QCB and Basel III requirements stood at 15.6% as at 30 June 2017, higher than the regulatory minimum requirements of the Qatar Central Bank and Basel Committee. The Group is keen to maintain a strong capitalisation in order to support future growth targets.

Based on the Group’s continuous strong performance and its diversified international presence, QNB is now the most valuable banking brand in the MEA region, with the value of its brand increased to USD3.8 billion to rise to the 60th place globally, in addition to attaining the highest rating of AA+ in brand strength. The total number of staff for the Group is more than 27,900 operating from 1,250 locations and 4,300 ATMs serving more than 21 million customers.

*Source: ME NewsWire

Contact information

QNB Group
Maha Mubarak Ali, +97444975704
PR@qnb.com.qa

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 21:33Tiedote

The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 15:09Tiedote

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 14:26Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s

NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 10:00Tiedote

NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve

Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 08:00Tiedote

Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme